Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 65 articles: HTML format

Single Articles

March 2023
1. ZHANG X, Wang H, Liu W, Xiao Z, et al
   Molecular features and evolutionary trajectory of ASCL1(+) and NEUROD1(+) SCLC cells.
   Br J Cancer. 2023;128:748-759.
   PubMed     Abstract available
   
   
   February 2023
2. LUO J, Hendryx M, Dong Y
   Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.
   Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02177.
   PubMed     Abstract available
   
   
   
3. LEYDEN GM, Greenwood MP, Gaborieau V, Han Y, et al
   Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation.
   Br J Cancer. 2023;128:618-625.
   PubMed     Abstract available
   
   
   
4. GOBERDHAN DCI
   Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival.
   Br J Cancer. 2023;128:471-473.
   PubMed     Abstract available
   
   
   
5. WORTH KR, Papandreou I, Hammond EM
   How the histological structure of some lung cancers shaped almost 70 years of radiobiology.
   Br J Cancer. 2023;128:407-412.
   PubMed     Abstract available
   
   
   January 2023
6. CHAN CH, Chiou LW, Lee TY, Liu YR, et al
   PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib.
   Br J Cancer. 2023;128:148-159.
   PubMed     Abstract available
   
   
   
7. CERONE MA, Mills TC, Sharpe R, McBride D, et al
   The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
   Br J Cancer. 2023;128:161-164.
   PubMed     Abstract available
   
   
   December 2022
8. ZHANG X, Yu Z, Xu Y, Chao Y, et al
   Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.
   Br J Cancer. 2022;127:2154-2165.
   PubMed     Abstract available
   
   
   November 2022
9. WU Z, Yao T, Wang Z, Liu B, et al
   Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis.
   Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02029.
   PubMed     Abstract available
   
   
   
10. BEHAR HARPAZ S, Weber MF, Wade S, Ngo PJ, et al
    Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.
    Br J Cancer. 2022 Nov 3. pii: 10.1038/s41416-022-02026.
    PubMed     Abstract available
    
    
    
11. NGUYEN TT, Lee HS, Burt BM, Amos CI, et al
    A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
    Br J Cancer. 2022;127:1691-1700.
    PubMed     Abstract available
    
    
    
12. HILTBRUNNER S, Fleischmann Z, Sokol ES, Zoche M, et al
    Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Br J Cancer. 2022;127:1997-2005.
    PubMed     Abstract available
    
    
    October 2022
13. MARINELLO J, Arleo A, Russo M, Delcuratolo M, et al
    Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway.
    Br J Cancer. 2022;127:1214-1225.
    PubMed     Abstract available
    
    
    
14. SARKAR BHATTACHARYA S, Thirusangu P, Jin L, Staub J, et al
    PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM.
    Br J Cancer. 2022;127:1352-1364.
    PubMed     Abstract available
    
    
    September 2022
15. ZULATO E, Del Bianco P, Nardo G, Attili I, et al
    Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2022 Sep 29. pii: 10.1038/s41416-022-01978.
    PubMed     Abstract available
    
    
    
16. WANG Y, Han H, Zhang F, Lv T, et al
    Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
    Br J Cancer. 2022 Sep 5. pii: 10.1038/s41416-022-01930.
    PubMed    
    
    
    
17. RIZZO A
    Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
    Br J Cancer. 2022 Sep 5. pii: 10.1038/s41416-022-01929.
    PubMed    
    
    
    
18. LI H, Sun Z, Xiao R, Qi Q, et al
    Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.
    Br J Cancer. 2022;127:747-756.
    PubMed     Abstract available
    
    
    
19. GARCIA-PARDO M, Makarem M, Li JJN, Kelly D, et al
    Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
    Br J Cancer. 2022;127:592-602.
    PubMed     Abstract available
    
    
    
20. ZHANG Y, Liu X, Zeng L, Zhao X, et al
    Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01956.
    PubMed     Abstract available
    
    
    
21. WANG Y, Han H, Zhang F, Lv T, et al
    Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
    Br J Cancer. 2022;127:948-956.
    PubMed     Abstract available
    
    
    June 2022
22. LYTHGOE MP, Prasad V
    Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
    Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01893.
    PubMed     Abstract available
    
    
    May 2022
23. MIN HY, Lee HJ, Suh YA, Pei H, et al
    Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
    PubMed     Abstract available
    
    
    
24. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available
    
    
    
25. EDWARDS CJ, Sette A, Cox C, Di Fiore B, et al
    The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
    Br J Cancer. 2022;126:1168-1177.
    PubMed     Abstract available
    
    
    April 2022
26. ZHANG B, Stewart CA, Wang Q, Cardnell RJ, et al
    Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01811.
    PubMed     Abstract available
    
    
    
27. MURCIANO-GOROFF YR, Pak T, Mondaca S, Flynn JR, et al
    Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers.
    Br J Cancer. 2022;126:889-898.
    PubMed     Abstract available
    
    
    March 2022
28. BONANNO L, Dal Maso A, Pavan A, Zulato E, et al
    Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
    Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01777.
    PubMed     Abstract available
    
    
    February 2022
29. WEI S, Liu W, Xu M, Qin H, et al
    Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer.
    Br J Cancer. 2022 Feb 25. pii: 10.1038/s41416-022-01744.
    PubMed     Abstract available
    
    
    
30. ZHANG P, Chen PL, Li ZH, Zhang A, et al
    Association of smoking and polygenic risk with the incidence of lung cancer: a prospective cohort study.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01736.
    PubMed     Abstract available
    
    
    
31. PATEL AJ, Tan TM, Richter AG, Naidu B, et al
    A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.
    Br J Cancer. 2022;126:238-246.
    PubMed     Abstract available
    
    
    November 2021
32. TAMMINGA M, Andree KC, van den Bos H, Hiltermann TJN, et al
    Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Br J Cancer. 2021 Nov 30. pii: 10.1038/s41416-021-01634.
    PubMed     Abstract available
    
    
    
33. CAMINA N, Penning TM
    Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer.
    Br J Cancer. 2021 Nov 29. pii: 10.1038/s41416-021-01642.
    PubMed     Abstract available
    
    
    
34. ALIAGAS E, Alay A, Martinez-Iniesta M, Hernandez-Madrigal M, et al
    Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Br J Cancer. 2021;125:1365-1376.
    PubMed     Abstract available
    
    
    
35. GARINET S, Didelot A, Denize T, Perrier A, et al
    Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC.
    Br J Cancer. 2021;125:1544-1551.
    PubMed     Abstract available
    
    
    October 2021
36. BALL S, Hyde C, Hamilton W, Bright CJ, et al
    An evaluation of a national mass media campaign to raise public awareness of possible lung cancer symptoms in England in 2016 and 2017.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01573.
    PubMed     Abstract available
    
    
    
37. HOPKINS AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, et al
    Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Br J Cancer. 2021 Oct 28. pii: 10.1038/s41416-021-01606.
    PubMed     Abstract available
    
    
    
38. MARTINEZ-MARTI A, Felip E, Mancuso FM, Caratu G, et al
    Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
    Br J Cancer. 2021 Oct 1. pii: 10.1038/s41416-021-01558.
    PubMed     Abstract available
    
    
    September 2021
39. LINDSAY CR, Shaw EC, Moore DA, Rassl D, et al
    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
    Br J Cancer. 2021 Sep 6. pii: 10.1038/s41416-021-01407.
    PubMed     Abstract available
    
    
    August 2021
40. ROSELL R, Cardona AF, Arrieta O, Aguilar A, et al
    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01519.
    PubMed     Abstract available
    
    
    
41. NI Y, Peng J, Yang X, Wei Z, et al
    Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.
    Br J Cancer. 2021;125:672-678.
    PubMed     Abstract available
    
    
    
42. LAPIDOT M, Case AE, Weisberg EL, Meng C, et al
    Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
    Br J Cancer. 2021;125:582-592.
    PubMed     Abstract available
    
    
    
43. JORDAN AM
    Molecularly profiled trials: toward a framework of actions for the "nil actionables".
    Br J Cancer. 2021;125:473-478.
    PubMed     Abstract available
    
    
    July 2021
44. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available
    
    
    
45. MU W, Katsoulakis E, Whelan CJ, Gage KL, et al
    Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2021;125:229-239.
    PubMed     Abstract available
    
    
    
46. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
    CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
    Br J Cancer. 2021;125:176-189.
    PubMed     Abstract available
    
    
    
47. GUO L, Kaumaya PTP
    First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.
    Br J Cancer. 2021;125:152-154.
    PubMed     Abstract available
    
    
    June 2021
48. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available
    
    
    May 2021
49. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01439.
    PubMed    
    
    
    
50. CHENG Y, Wang Q, Li K, Shi J, et al
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01356.
    PubMed     Abstract available
    
    
    
51. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 May 17. pii: 10.1038/s41416-021-01436.
    PubMed    
    
    
    
52. ROUND T, L'Esperance V, Bayly J, Brain K, et al
    COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01361.
    PubMed     Abstract available
    
    
    
53. LIN JJ, Gainor JF
    An early look at selective RET inhibitor resistance: new challenges and opportunities.
    Br J Cancer. 2021;124:1757-1758.
    PubMed     Abstract available
    
    
    
54. LARIJANI B, Miles J, Ward SG, Parker PJ, et al
    Quantification of biomarker functionality predicts patient outcomes.
    Br J Cancer. 2021;124:1618-1620.
    PubMed     Abstract available
    
    
    April 2021
55. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01278.
    PubMed     Abstract available
    
    
    March 2021
56. YANG H, Hall SRR, Sun B, Yao F, et al
    Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1177-1178.
    PubMed    
    
    
    
57. WHITE MG, Eng OS
    Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1179-1180.
    PubMed    
    
    
    
58. JIA L, Ge X, Du C, Chen L, et al
    EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-beta/SMAD signalling.
    Br J Cancer. 2021;124:1301-1311.
    PubMed     Abstract available
    
    
    
59. SHIRASAWA M, Yoshida T, Horinouchi H, Kitano S, et al
    Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
    Br J Cancer. 2021;124:925-932.
    PubMed     Abstract available
    
    
    February 2021
60. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    
61. WHITE MG, Schulte JJ, Xue L, Berger Y, et al
    Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
    Br J Cancer. 2021;124:564-566.
    PubMed     Abstract available
    
    
    January 2021
62. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available
    
    
    
63. SUGANO T, Masuda M, Takeshita F, Motoi N, et al
    Pharmacological blockage of transforming growth factor-beta signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
    Br J Cancer. 2021;124:228-236.
    PubMed     Abstract available
    
    
    
64. BAE K, Kim JH, Jung H, Kong SY, et al
    A fusion of CD63-BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis.
    Br J Cancer. 2021;124:290-298.
    PubMed     Abstract available
    
    
    December 2020
65. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: